Some markers of neuronal damage in cerebrospinal fluid of multiple sclerosis patients in relapse

Folia Neuropathologica

Volumn 49, Issue 3, 2011, Pages 191-196

  Mitosek Szewczyk, Krystyna ^a   Gordon Krajcer, Wanda ^b   Flis, Dorota ^c   Stelmasiak, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c I Independent Clinical Hospital Lublin   (Poland)

Author keywords

A amyloid protein; Multiple sclerosis; Neurofilament; Neuron specific enolase; S 100B; Tau and phospho tau proteins; APP

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; NEURON SPECIFIC ENOLASE; PROTEIN S100B; TAU PROTEIN;

ADULT; ARTICLE; ASTROCYTE; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROFILAMENT; PATHOGENICITY; RELAPSE;

EID: 80053498585     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Armstrong RA. A spatial pattern analysis of β-amyloid (Aβ) deposition in the temporal lobe in Alzheimer's disease. Folia Neuropathol 2010; 48: 67-74.
2. Armstrong RA. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease. Folia Neuropathol 2009; 47: 289-299.
3. Blennow K. Cerebrospinal fluid protein biomarkers for Alz hei - mer's disease. NeuroRx 2004; 1: 213-225. (Pubitemid 46589353)
4. Brettschneider J, Petzold A, Junker A, Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Multiple Scler 2006; 12: 143-148.
5. Carmel G, Mager EM, Binder LI, Kuret J. The structural basis of monoclonal antibody Alz50's selectively for Alzheimer's disease pathology. J Biol Chem 1996; 271: 32789-32795. (Pubitemid 27008707)
6. Conçalves C-A, Leite MC, Nardin P. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 2008; 41: 755-763.
7. Currie JR, Ramakrishna N, Burrage TG, Hwang M-C, Potempska A, Miller DL, Mehta PD, Kim KS, Wisniewski HM. Immunolocalization of Alzheimer β-amyloid peptide precursor to cellular membranes in baculovirus expression system J Neurosci Res 1991; 30: 687-698.
8. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003; 60: 540-551.
9. Fesenmeier JT, Whitaker JN, Herman PK, Walker DP. Cerebrospinal fluid levels of myelin basic protein-like material and soluble interleukin-2 receptor in multiple sclerosis. J Neuroimmunol 1991; 34: 77-80.
10. Gehrmann J, Banati RB, Cuzner ML, Kreutzberg GW, Newcombe J. Amyloid precursor protein (APP) expression in multiple sclerosis lesions. Glia 1995; 15: 141-151.
11. Genteleman SM, Nash MJ, Sweeting CJ, Graham DI, Roberts GW. Beta-amyloid precursor protein (beta-APP) as a marker for axonal injury after head trauma. Neurosci Lett 1993; 160: 139-144. (Pubitemid 23294725)
12. Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognizes tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett 1995; 189: 167-169.
13. Green AJ, Keir G, Thompson EJ. A specific and sensitive ELISA for measuring S-100b in cerebrospinal fluid. J Immunol Methods 1997; 205: 35-41. (Pubitemid 27297832)
14. Guimaraes J, Cardoso MJ, Sa MJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Multiple Scler 2006; 12: 354-356. (Pubitemid 43827192)
15. Hardemark H, Ericsson N, Kotwica Z, Rundström G, Mendel- Hartvig I, Olsson Y, Pahlman S, Persson L. S-100 protein and neuron specific enolase in CSF after experimental traumatic or focal ischemic brain damage. J Neurosurg 1989; 71: 727-731. (Pubitemid 19275772)
16. Hu YY, He SS, Wang XC, Duan QH, Khatoon S, Iqbal K, Grundke- Iqbal I, Wang JZ. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 2002; 320: 156-160. (Pubitemid 34164438)
17. Jimenez- Jimenez FJ, Zurdo JM, Hernanz A, Medina-Acebron, de Bustos F, Barcenilla B, Sayed Y, Ayuso-Peralta L. Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand 2002; 106: 351-354.
18. Kalaria RN, Bhatti SU, Palatinsky EA, Pennington DH, Shelton ER, Chan HW, Perry G, Lust WD. Accumulation of the β-amyloid precursor protein at sites of ischemic injury in rat brains. Neuro Report 1993; 4: 211-214. (Pubitemid 23080879)
19. Kim KS, Wen G, Bancher C, Chen CJ, Sapienza VJ, Hong H, Wisniewski HM. Detection and quantitation of amyloid β-peptide with 2 monoclonal antibodies. Neurosci Res Commun 1990; 7: 113-122.
20. Kleindienst A, Ross Bullock M. A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. J Neurotrauma 2006; 2: 1185-1200. (Pubitemid 44681474)
21. Kosik KS, Orecchio LD, Binder LI, Trojanowski J, Lee VMY, Lee G. Epitopes that span the tau molecule are shared with paired helical filaments. Neuron 1988; 1: 817-825.
22. Kurtzke JE. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
23. Lamers KJ, van Engelen BG, Gabreels FJ, Hommes OR, Borm GF, Wevers RA. Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders. Acta Neurol Scand 1995; 92: 247-251.
24. Mattson MP. Cellular actions of β-Amyloid Precursor Protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997; 77: 1081-1132. (Pubitemid 27459580)
25. Massaro AR, Michetti F, Laudisio A, Bergonzi P. Myelin basic protein and S-100 antigen in cerebrospinal fluid of patients with multiple sclerosis in the acute phase. Ital J Neurol Sci 1985; 6: 53-56.
26. McDonald, WI, Compston A, Sdan G, Goodkin D, Hartung HP, Lublin FD, MaFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, von den Noot S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
27. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wiśniewski HM. Plasma and cerebrospinal fluid levels of amyloid β proteins I-40 and I-42 in Alzheimer disease. Arch Neurol 2000; 57: 100-105. (Pubitemid 30027637)
28. Michałowska-Wender G, Losy J, Wender M. Biological markers to confirm diagnosis and monitor the therapy in multiple sclerosis patients. Folia Neuropathol 2001; 39: 1-5.
29. Petzold A, Keir G, Lim D, Smith M, Thompson EJ. Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern. Brain Res Bull 2003; 61: 281-185.
30. Pluta R, Kida E, Lossinsky AS, Golabek AA, Mossakowski MJ, Wiśniewski HM. Complete cerebral ischemia with short-term survival in rats induced by cardiac arrest: I. Extracellular accumulation of Alzheimer's β-amyloid protein precursor in the brain. Brain Res 1994; 649: 323-328. (Pubitemid 24197229)
31. Potempska J, Styles P, Mehta KS, Kim KS, Miller DL. Purification and tissue level of the β-amyloid peptide precursor of rat brain. J Biol Chem 1991; 266: 8464-8469. (Pubitemid 21906532)
32. Rosengren LE, Karlsson JE, Sjögren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999; 52: 1090-1093. (Pubitemid 29161631)
33. Rostasy K, Withut E, Pohl D, Lange P, Ciesielcyk B, Diem R, Gartner J, Otto M. Tau, phospho-tau, and S-100B in cerebrospinal fluid of children with multiple sclerosis. J Child Neurol 2005; 20: 822-825. (Pubitemid 43124472)
34. Rothermundt M, Peters M, Prehn JH, Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech 2003; 60: 614-632.
35. Rothoerl RD, Woertgen C, Holzschuh M, Metz C, Brawanski A. Rapid evaluation of S-100 serum levels. Case report and comparison to previous results. Brain Inj 1999; 13: 387-391. (Pubitemid 29229419)
36. Seubert P, Mawal-Dewan M, Barbour R, Jakes R, Goedert M, Johnson GVM, Litersky JM, Schenk D, Lieberburg I, Trojanowski JQ, Lee VMY. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J Biol Chem 1995; 270: 18917-18922.
37. Shahani N, Brandt R. Functions and malfunctions of the tau proteins. Cell Mol Life Sci 2002; 59: 1668-1680. (Pubitemid 35346971)
38. Sjögren M, Blomberg M, Jonsson M, Wahlund L-O, Edams A, Lind K, Rosengren L, Blennow K, Wallin A. Neurofilament protein in cerebral fluid: a marker of white matter changes. J Neurosci Res 2001; 66: 510-516. (Pubitemid 33027419)
39. Stephenson DT, Rash K, Clemens JA. Amyloid precursor protein accumulations in regions of neurodegeneration following focal cerebral ischemia in the rat. Brain Res 1992; 593: 128-135.
40. Sulkowski G, Dabrowska-Bouta B, Kwiatkowska-Patzer B, Struzynska L. Alterations in glutamate transport and group I metabotro - pic glutamate receptors in the rat brain during acute phase of experimental autoimmune encephalomyelitis. Folia Neuropathol 2009; 47: 329-337.
41. Szendrei GI, Lee VM, Otvos L, Jr. Recognition of the minimal epitope of monoclonal antibody Tau-1 depends upon the presence of a phosphate group but not on its location. J Neurosci Res 1993; 34: 243-249. (Pubitemid 23037325)
42. Terzi M, Birinci A, Cetinkaya E, Onar M.K. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol Scand 2007; 115: 325-330. (Pubitemid 46699430)
43. Tumani H, Hartung H-P, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, Zettl UK. The BioMS Study Group: Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 2009; 35: 117-127.
44. Wakita H, Tomimoto H, Akiguchi I, Ohnishi K, Nakamura S, Kiura J. Regional accumulation of amyloid β/A4 protein precursor in the gerbil brain following transient cerebral ischemia. Neurosci Lett 1992; 146: 135-138.
45. Yokota T, Saido TC, Tani E, Yamamura I, Minami N. Cytotoxic fragment of amyloid precursor protein accumulates in hippocampus after global forebrain ischemia. J Cereb Blood Flow Metab 1996; 16: 1219-1223. (Pubitemid 26365373)